|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.68 USD | +0.65% |
|
-8.25% | -30.73% |
| May. 24 | HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating | MT |
| May. 24 | Deutsche Bank Starts Legend Biotech With Buy Rating | MT |
Legend Biotech Corporation reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 93.99 million compared to USD 36.34 million a year ago. Net loss was USD 59.79 million compared to USD 112.1 million a year ago.
Basic loss per share from continuing operations was USD 0.32 compared to USD 0.68 a year ago. Diluted loss per share from continuing operations was USD 0.32 compared to USD 0.68 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -30.73% | 7.55B | |
| +9.83% | 118B | |
| +10.80% | 106B | |
| -10.84% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.11% | 15.97B | |
| +6.62% | 14.03B | |
| +17.53% | 11.67B |
LEGEND BIOTECH CORPORATION 
